Dec 30 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * REG-BIOPORTO ANNOUNCES CE MARK OF NEAR-PATIENT TEST FOR
KIDNEY
INJURY AND MILESTONES FOR GRAD PLATFORM TECHNOLOGY
    * OBTAINED CE MARKING IN EU FOR ITS NGALDS, A NOVEL
GRAD-BASED
TEST FOR NEAR-PATIENT MEASUREMENT OF NGAL, AND ANNOUNCES
COMMERCIAL LAUNCH
    * ITS NOVEL SARS-COV-2 RAPID TEST, ALSO BASED ON
GRAD-PLATFORM, IS
UNDERGOING CLINICAL TESTING AT UNIVERSITY OF CALIFORNIA, DAVIS

Source text for Eikon:  ID:nGNE9wLFDc 
Further company coverage:  BIOPOR.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))